Quest Diagnostics Incorporated reported significant financial performance improvements in its latest 10-Q filing for the second quarter of 2026. The company achieved net revenues of $3,043 million for the three months ended June 30, 2026, marking a 10.2% increase from $2,761 million in the same period of 2025. For the first half of 2026, net revenues rose to $5,938 million, up from $5,413 million in the prior year, reflecting a 9.7% growth. Net income attributable to Quest Diagnostics also increased, reaching $320 million for the second quarter, compared to $282 million in 2025, and $572 million for the first half of 2026, up from $502 million a year earlier.
The company's operating income for the second quarter was $459 million, a 4.6% increase from $438 million in the same quarter of 2025. Operating costs and expenses rose to $2,584 million, up 11.2% from $2,323 million, primarily driven by higher costs associated with services and selling, general, and administrative expenses. The increase in costs was attributed to higher compensation and supply expenses, although these were partially offset by productivity improvements from the company's ongoing Invigorate program, which aims to enhance efficiency and reduce costs.
Strategically, Quest Diagnostics completed a significant venture with Corewell Health, forming a new entity to perform laboratory testing in Michigan. This partnership, finalized in January 2026, is expected to enhance the company's service offerings and operational capabilities in the region. Additionally, the company has been actively engaged in its Invigorate program, which targets annual cost savings of 3% through various operational improvements, including automation and artificial intelligence.
Operationally, the company reported a 13.1% increase in requisition volume for the second quarter, driven by organic growth and new relationships with healthcare providers. However, revenue per requisition decreased by 2.8%, influenced by a shift in business mix due to the new partnerships. As of June 30, 2026, Quest Diagnostics had cash and cash equivalents totaling $626 million, an increase from $420 million at the end of 2025, indicating improved liquidity.
Looking ahead, Quest Diagnostics remains optimistic about its growth trajectory, supported by its strategic initiatives and operational efficiencies. The company anticipates continued revenue growth driven by its diagnostic information services, which account for over 95% of total revenues. The management's focus on enhancing productivity and expanding service offerings positions the company well for future performance, despite ongoing challenges in the healthcare landscape.
About QUEST DIAGNOSTICS INC
Quest Diagnostics is a leading provider of diagnostic testing and information services, serving healthcare providers, hospitals, patients, and payers primarily in the U.S. The company offers routine, advanced, and molecular diagnostics, leveraging extensive data assets, innovative technology, and a broad network of laboratories and patient centers. Its core value lies in delivering high-quality, accessible insights to improve health outcomes and support value-based care.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov